GlassScriptPhysician profile
Vandan Patel
NPI 1821626391
$817.62
in general payments reported to CMS, 2019-2025
10 companies · $353 in 2025
The $353 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $110 · 2024: $354 · 2025: $353.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $480 · Education: $337.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $480.46 |
| Education | $337.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $246.06 | 2025 | Ensite, Mitraclip |
| Boehringer Ingelheim Pharmaceuticals, INC. | $177.69 | 2024-2025 | Spevigo |
| Janssen Biotech, INC. | $143.69 | 2024 | Tremfya |
| Boston Scientific Corporation | $93.38 | 2023 | Lux-Dx Insertable Cardiac Monitor |
| Lilly USA, LLC | $49.13 | 2024-2025 | Ebglyss, Taltz, Olumiant |
| Abbvie INC. | $35.08 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $21.03 | 2025 | Dupixent |
| Kestra Medical Technology Services, INC. | $17.78 | 2025 | Assure Wcd |
| Abiomed | $16.92 | 2025 | |
| Incyte Corporation | $16.86 | 2023 | Opzelura |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vandan Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.